To assess the effect of SREBP1 on gallbladder cancer cell survival and resistance to gemcitabine, we added 10 μmol/L gemcitabine to NOZ cells treated with si‐SREBP1 or si‐Control and verified the silencing of SREBP1 in NOZ cells by WB analysis (Figure 5C). Here, SREBF1 is linked to gallbladder cancer.